Louis Navellier’s #1 Stock for 2022

On October 20, the man who recommended Google before anyone else will reveal his #1 stock pick for 2022 — for FREE — ticker symbol and all — in a special presentation.

Wed, October 20 at 4:00PM ET
 
 
 
 

5 Life Sciences Tools & Services Stocks to Sell Now

The ratings of 5 Life Sciences Tools & Services stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Charles River Laboratories International, Inc. (CRL) gets weaker ratings this week as last week’s C drops to a D. Charles River Laboratories International, Inc. is a global provider of services to accelerate the drug discovery and development process. For more information, get Portfolio Grader’s complete analysis of CRL stock.

QIAGEN NV (QGEN) slips from a C to a D this week. QIAGEN NV provides sample and assay technologies. For more information, get Portfolio Grader’s complete analysis of QGEN stock.

This is a rough week for Pacific Biosciences of California, Inc. (PACB). The company’s rating falls to D from the previous week’s C. Pacific Biosciences of California, Inc. has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. The company also gets F’s in earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of PACB stock.

Fluidigm Corporation (FLDM) earns a F this week, moving down from last week’s grade of D. Fluidigm Corporation develops, manufactures, and markets proprietary Integrated Fluidic Circuit systems. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLDM stock.

Slipping from a D to a F rating, Genetic Technologies Limited Sponsored ADR (GENE) takes a hit this week. Genetic Technologies Limited Sponsored ADR is a biotechnology company that practices advanced DNA genetic research and testing. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GENE stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/12/5-life-sciences-tools-services-stocks-to-sell-now-2/.

©2021 InvestorPlace Media, LLC